

# Associations between vaginal microbiota, bacterial vaginosis and urinary tract infections in a premenopausal population

**Authors:** Natasha L. Wild\*<sup>1,2</sup>, Lenka A. Vodstrcil<sup>1,2,3</sup>, Laura G. Matthews<sup>1,2</sup>, Kay Htaik<sup>1,2</sup>, Rosie L. Latimer<sup>1</sup>, Gerald L. Murray<sup>4,5,6</sup>, Jennifer A. Danielewski<sup>4,5,6</sup>, Erica L. Plummer<sup>1,2</sup>, Catriona S. Bradshaw<sup>1,2,3</sup>

<sup>1</sup>School of Translational Medicine, Monash University, Melbourne, Australia

<sup>2</sup>Melbourne Sexual Health Centre, Bayside Health, Melbourne, Australia

<sup>3</sup>Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia

<sup>4</sup>Centre for Women's Infectious Diseases, Royal Women's Hospital, Parkville, VIC, Australia

<sup>5</sup>Molecular Microbiology Research Group, Murdoch Children's Research Institute, Parkville, VIC, Australia

<sup>6</sup>Department of Obstetrics, Gynaecology, and Newborn Health, University of Melbourne, Parkville, VIC, Australia

\*Presenting author

**Background:** Epidemiological data and anecdotal reports suggest bacterial vaginosis (BV) may increase the risk of urinary tract infection (UTI). *In-vitro* studies and research in peri- and post-menopausal populations indicate a protective role of vaginal lactobacilli against UTIs. However, the influence of BV and the vaginal microbiome on UTI risk in pre-menopausal populations is understudied.

**Methods:** This case-control study utilised epidemiological, clinical, and 16S rRNA gene-sequenced vaginal microbiota data from pre-menopausal people with a vagina enrolled in the OMG study between 2017 and 2019 at the Melbourne Sexual Health Centre. Three case groups were defined; participants with i) urinary symptoms (dysuria and/or frequency, n=544), ii) UTI-positivity (positive urine dipstick and/or microscopy, n=127), and iii) uropathogen-positivity (UTI-positive with a uropathogenic isolate on culture, n=55). We investigated factors associated with each case group compared to an asymptomatic control group (n=180) in multivariable models (including variables with p<0.2 in univariable analyses). Differential abundance analyses were performed to identify under/overrepresented bacterial species in each case group relative to controls.

**Results:** BV was significantly associated with urinary symptoms (adjusted-odds-ratio[AOR]=2.70, 95%CI=1.58-4.59, p<0.001) and diagnosis of a UTI (AOR=2.29, 95%CI=1.08-4.85, p=0.030) compared to controls. In cases with urinary symptoms, the relative abundance of *Gardnerella vaginalis* was also significantly greater than in controls (FDR-adjusted p-value=0.025). Conversely, an optimal vaginal microbiome composition was negatively associated with urinary symptoms (AOR=0.66, 95%CI=0.46-0.94, p=0.027) and diagnosis of a UTI (AOR=0.46, 95%CI=0.26-0.80, p=0.006). The relative abundance of *Lactobacillus crispatus* was significantly lower in all three case groups compared with controls (FDR-adjusted p-value [urinary symptoms=0.001; UTI-positivity=0.011; uropathogen-positivity=0.056]).

**Conclusion:** Our results suggest *L. crispatus* and an optimal vaginal microbiome are protective against UTIs in our pre-menopausal population. Furthermore, we report a positive association between BV and urinary symptoms and UTIs. These findings may support BV testing and treatment as an important facet of UTI prevention and management.

**Disclosure of Interest Statement:** The authors have no conflicts of interest to declare.